Sandra Horning Abstract 349 Sandra Horning, Stanford University Medical Center It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine, predinsone) induction therap
Sandra Horning
Abstract 349Sandra Horning, Stanford University Medical CenterIt is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine, predinsone) induction therapy in patients with advanced follicular lymphoma. However, the use of rituximab maintenance, after induction therapy, brought clear benefits among patients in the study.Click here for all the interviews from ASH 2005
Related Episodes
New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia
Audio Journal of Oncology SAN DIEGO—The first-line treatment of choice for older patients with chronic lymphocytic leukemia (CLL) should now be single agent ibrutinib according to conclu
Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?
SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irrev
Chimeric antigen receptor T-cell therapy: high remission rate in relapsed, refractory acute lymphoblastic leukemia
NEW ORLEANS—High remission rates with extended survival are being achieved in patients who had failed all other therapies — including allogeneic stem cell transplantation — for their acute lymphoblast